Answers are grounded in this paper and cite their sources.
Background: Currently, a large number of new anticancer agents is accompanied by constrained resources, requiring prioritization. In addition, emerging molecular subtypes subdivide common cancer entities into rare diseases, making it harder to conduct phase II trials as a crucial step in drug development and therapy optimization. We extend a recent work by Khan et al. on the design of phase II clinical trial based on exact binomial tests.
No takes yet. Share an insight, caveat, or question.
Dirk Klingbiel (2015) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: